MedTrace Logo

Paclitaxel

Drug

Drug Profile

Paclitaxel is a taxane antineoplastic chemotherapy drug used in multiple solid tumors including breast, ovarian, lung, and Kaposi's sarcoma settings. It acts on microtubules to arrest mitosis and induce tumor-cell death. Paclitaxel was approved for medical use in 1993.

Drug Class
Taxane mitotic inhibitor
Approval Status
Approved for medical use in 1993.
Mechanism of Action
Stabilizes microtubule polymer and protects it from disassembly, disrupting mitotic spindle function and triggering apoptosis.
Brand Names
  • Taxol
  • Onxol
Indications
  • \Breast cancer\
  • \Ovarian cancer\
  • \Non-small cell lung cancer\
  • \Kaposi's sarcoma\

Related News

High Biomarker Testing Rates Achieved Across Racial Groups in Metastatic Triple-Negative Breast Cancer, Yet Disparities Persist

A study of 450 mTNBC patients in community practices found high biomarker testing rates and encouraging outcomes across racial groups, with Hispanic patients showing the longest survival. However, Black women of West African ancestry face the highest TNBC incidence and greater neuropathy from paclitaxel, making docetaxel a potential alternative. Social determinants like neighborhood deprivation and allostatic load are also linked to TNBC risk.

Nanomaterial Strategies Advance Cancer Immunotherapy, Studies Show

A review and two studies report advances in nanomaterial-based cancer immunotherapy, including engineered nanoparticles that boost immunogenic tumor cell death, nanosheet artificial antibodies that block PD-L1, and design principles for overcoming delivery barriers. These approaches aim to improve immune activation and reduce off-target effects.

PanTher Completes PTM-101 Dose Escalation in Pancreatic Cancer Trial

PanTher Therapeutics completed dose escalation in its Phase 1b trial of PTM-101 for pancreatic cancer, identifying 400mg as the recommended Phase 2 dose. Other pancreatic cancer updates include ASCO 2026 RASolute 302 data, a Nature study on NDRG1, and a giant acinar cell carcinoma case report.

Related Clinical Trials

NCT ID Title Status Phase
NCT07776340

Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC

 NOT_YET_RECRUITING PHASE2
NCT07775040

Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial

 NOT_YET_RECRUITING PHASE2
NCT07768436

A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer

 RECRUITING PHASE2
NCT07757022

AI-Driven Digital Twin and Drug Simulation for Esophageal Cancer

 NOT_YET_RECRUITING
NCT07756645

A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants

 NOT_YET_RECRUITING PHASE3
NCT07743164

A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

 NOT_YET_RECRUITING PHASE3
NCT07739199

A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)

 NOT_YET_RECRUITING PHASE2/PHASE3
NCT07699185

Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma

 RECRUITING PHASE2
NCT07690787

JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma

 RECRUITING PHASE2
NCT07684612

A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)

 NOT_YET_RECRUITING PHASE3